Robert Loberg

Robert Loberg serves as a HealthTech Advisory Board Member at Cota Capital since September 2022, while also holding the position of Vice President, Lifecycle Leader - Oncology & Genetics at Roche since June 2020. In this role, Robert leads the development and commercialization of next-generation sequencing assays and oncology PCR products, managing a multifunctional Global Lifecycle Team and overseeing product strategies. Previously, Robert spent over a decade at Amgen, advancing through various roles including Executive Director, where responsibilities encompassed biomarker and diagnostic strategy, leadership of a diverse team, and management of numerous clinical programs. An academic background includes tenure as an Assistant Professor at the University of Michigan Medical Center, focusing on urologic oncology research. Robert holds a PhD in Physiology from the University of Michigan, along with a MS and BA in Physiology and Biology from Baylor University, respectively.